Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Horizon Europe · Cluster 1 – Health · HORIZON-HLTH-2027-01-DISEASE-07
Funding to advance monoclonal antibodies against viruses such as Ebola, Marburg or Chikungunya, up to first clinical trials.
What is this call about?
The topic funds research and innovation projects that advance existing monoclonal antibody candidates against selected filo-, nairo-, phenui-, picorna- and togaviruses from preclinical tests to first-in-human safety studies.
What does this call fund?
Scope
The topic funds the further development of existing prophylactic and therapeutic monoclonal antibody candidates against selected filo-, nairo-, phenui-, picorna- and togaviruses, in support of the European Medical Countermeasures Strategy. Each proposal should explicitly state which one of the following viruses it targets, and the work should address only that virus:
- Ebola virus;
- Marburg virus;
- Crimean-Congo haemorrhagic fever virus;
- Rift Valley fever virus;
- Enterovirus D68;
- Chikungunya virus.
Proposals should focus on antibodies produced or derived from a single cell clone through recombinant expression, such as B-cell derived antibodies, hybridoma derived antibodies and nanobodies.
Research areas
Proposals should address all of the following:
- where necessary, completing in-vitro characterisation of the candidates (target specificity, epitope and ability to impair viral functions);
- in-vivo tests in at least one animal model, or in humanised immune system animal models where available, and in non-human primates if regulators require it;
- evaluation of antibody-dependent enhancement risk where scientifically relevant;
- production of GMP batches of the most promising candidates;
- first-in-human clinical safety studies with a clear regulatory pathway to market authorisation.
Attention should be paid to sex, age, ethnicity and disability. Projects should engage with regulators in good time and use existing research infrastructures, such as those that contributed to ISIDORe services.
Expected outcomes
Better understanding of and access to experimental monoclonal antibodies for emerging and re-emerging viral infections, and candidate antibody therapies available for clinical use in an epidemic or pandemic.
What are the key facts?
- Topic budget
- €37,300,000
- Minimum amount per project
- €9,000,000
- Maximum amount per project
- €10,000,000
- Call code
- HORIZON-HLTH-2027-01-DISEASE-07
- Programme
- Horizon Europe
- Funder
- European Union, Horizon Europe
- Expected number of projects
- 4
Who can apply for this call?
- Participation of third countries where the targeted viruses are endemic or where outbreaks have occurred or are ongoing is encouraged.
- The participation of start-ups, micro, small and medium-sized enterprises is encouraged.
- Applicants should describe their clinical studies in the dedicated annex using the template in the submission system.
Check your eligibility and how your project fits
In your free account, we check the eligibility conditions against the call documents for your organisation and assess how well your project fits this call.
When is the deadline?
17 February 2027 (104 days)
13 April 2027 (single-stage call).
Interested in this call? Summary written with AI from the official call documents. Details can differ, so check the official call page before you apply. Read the official call documents before you decide. The official text is always binding.
Source: EU Funding & Tenders Portal and the official call documents. Official call page Last updated 6 October 2026.